Navellier & Associates Inc. Buys Shares of 44,943 Phibro Animal Health Corporation (NASDAQ:PAHC)

Key Points

• Navellier & Associates Inc. acquired a new stake in Phibro Animal Health Corporation, purchasing 44,943 shares valued at approximately $878,000.
• The stock of Phibro Animal Health recently reported a 0.63 earnings per share (EPS), exceeding the consensus estimate by $0.11, despite revenues falling short of analyst expectations.
• Several analysts have set new price targets for Phibro Animal Health, with JPMorgan Chase raising their target from $25.00 to $35.00, after upgrading the stock from "neutral" to "overweight."

Navellier & Associates Inc. bought a new stake in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 44,943 shares of the company's stock, valued at approximately $878,000. Navellier & Associates Inc. owned approximately 0.11% of Phibro Animal Health as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Sterling Capital Management LLC increased its position in shares of Phibro Animal Health by 2.4% during the 4th quarter. Sterling Capital Management LLC now owns 18,762 shares of the company's stock worth $394,000 after purchasing an additional 448 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Phibro Animal Health during the 4th quarter worth approximately $29,000. Price T Rowe Associates Inc. MD increased its position in shares of Phibro Animal Health by 9.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,668 shares of the company's stock worth $372,000 after purchasing an additional 1,565 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Phibro Animal Health by 2,739.7% during the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after purchasing an additional 1,589 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Phibro Animal Health by 18.9% during the 1st quarter. Cetera Investment Advisers now owns 11,550 shares of the company's stock worth $247,000 after purchasing an additional 1,840 shares during the last quarter. Institutional investors own 99.34% of the company's stock.

Phibro Animal Health Stock Performance

NASDAQ PAHC traded down $0.82 on Tuesday, reaching $28.10. The stock had a trading volume of 134,945 shares, compared to its average volume of 259,494. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The firm has a fifty day moving average of $26.40 and a two-hundred day moving average of $23.14. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $31.80. The company has a market cap of $1.14 billion, a P/E ratio of 35.97, a price-to-earnings-growth ratio of 0.49 and a beta of 0.75.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. The firm had revenue of $347.80 million for the quarter, compared to analyst estimates of $352.41 million. On average, equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Wednesday, June 4th were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date of this dividend was Wednesday, June 4th. Phibro Animal Health's dividend payout ratio is 61.54%.

Analyst Ratings Changes

Several research firms have weighed in on PAHC. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $25.00 to $35.00 in a report on Monday, July 7th. BNP Paribas raised Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price on the stock in a report on Monday, June 16th. Finally, Morgan Stanley set a $26.00 target price on Phibro Animal Health and gave the stock an "equal weight" rating in a report on Wednesday, June 25th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $24.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.